Egis-11150 : A candidate antipsychotic compound with procognitive efficacy in rodents

Gacsályi, István and Nagy, Katalin and Pallagi, Katalin and Lévay, György István and Hársing, László Gábor and Haller, József and Szénási, Gábor (2013) Egis-11150 : A candidate antipsychotic compound with procognitive efficacy in rodents. NEUROPHARMACOLOGY, 64 (1). pp. 254-263. ISSN 0028-3908

Text haller 4.pdf Restricted to Repository staff only Download (1MB) | Request a copy

Abstract

Classical antipsychotics, e.g. haloperidol, chlorpromazine, are potent at controlling the positive symptoms of schizophrenia but frequently elicit extrapyramidal motor side-effects. The introduction of atypical antipsychotics such as risperidone, olanzapine and clozapine has obviated this problem, but none of the current drugs seem to improve the cognitive deficits accompanying schizophrenia. Thus there is an unmet need for agents that not only suppress the psychotic symptoms but also ameliorate the impairment of cognition. Here, we report the preclinical properties of a candidate antipsychotic, Egis-11150, that shows marked pro-cognitive efficacy. Egis-11150 displayed high affinity for adrenergic alpha(1), alpha(2c), 5-HT(2A) 5-HT(7), moderate affinity for adrenergic alpha(2a) and D(2) receptors. It was a functional antagonist on all of the above receptors, with the exception of 5-HT(7) receptors, where it was an inverse agonist. Phencyclidine-induced hypermotility in mice and inhibition of conditioned avoidance response in rats were assessed to estimate efficacy against the positive and social withdrawal test in rats was used to predict efficacy against the negative symptoms of schizophrenia. Passive-avoidance learning, novel object recognition and radial maze tests in rats were used to assess pro-cognitive activity, while phencyclidine-induced disruption of prepulse inhibition in mice was examined to test for effects on attention. Egis-11150 (0.01-0.3 mg/kg, ip.) was effective in all of the preclinical models of schizophrenia examined. Moreover, a robust pro-cognitive profile was apparent. In summary, work in preclinical models indicates that Egis-11150 is a potential treatment for controlling the psychosis as well as the cognitive dysfunction in schizophrenia. This article is part of a Special Issue entitled 'Cognitive Enhancers'.

Actions (login required)

Edit Item